Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cell proliferation assay, colony formation assay and flow cytometry were carried out to evaluate the role of p90/CIP2A in cell proliferation and apoptosis. p90/CIP2A depletion in breast cancer cells inhibited proliferation and increased paclitaxel-induced apoptosis.
|
25086622 |
2014 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CIP2A expression also significantly related to chemotherapeutic sensitivity of breast cancer in the neoadjuvant chemotherapy.
|
23471718 |
2013 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently identified oncoprotein that is overexpressed in breast cancer.
|
28938602 |
2017 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The p90 ribosomal S6 kinase (RSK) is a family of MAPK-activated serine/threonine kinases (RSK1-4) whose expression and/or activity are deregulated in several cancers, including breast cancer.
|
27028868 |
2016 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data point to CIP2A and PP2A as novel therapeutic targets for AI-resistant breast cancer.
|
29805747 |
2018 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The second part emphasizes the overexpression of SET and CIP2A in cancer progression, and the anticancer activity of SET antagonists as follows: (5) isolation and characterization of SET; (6) isolation and characterization of CIP2A; (7) progression of leukemia with SET; (8) progression of breast cancer with SET and CIP2A; (9) progression of lung cancer with SET; (10) anti-carcinogenic effects of SET antagonists OP449 and FTY720; and also (11) TNF-α-inducing protein of Helicobacter pylori, which is a clinical example of the okadaic acid pathway.
|
30341686 |
2018 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Loss of CIP2A also inhibited anchorage-independent growth in breast cancer cells.
|
19671842 |
2009 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of SET or CIP2A reduces the tumorigenic potential of breast cancer cell lines both in vitro and in vivo.
|
24927563 |
2014 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these results implicate the E2F1-CIP2A feedback loop as a key determinant of breast cancer cell sensitivity to senescence induction.
|
23306062 |
2013 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CIP2A protein expression was studied by immunohistochemistry in oestrogen receptor-positive primary breast cancers (n = 250) obtained from the Leeds Tissue Bank.
|
29034804 |
2017 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The serum CIP2A levels in patients with breast cancer were (79.0 ± 74.2) ng/mL, which was significantly higher than that in those controls (25.6 ± 21.4) ng/mL for male and (24.8 ± 20.6) ng/mL for female control.
|
26813457 |
2016 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data point to CIP2A and PP2A as novel therapeutic targets for AI-resistant breast cancer.
|
29805747 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cell proliferation assay, colony formation assay and flow cytometry were carried out to evaluate the role of p90/CIP2A in cell proliferation and apoptosis. p90/CIP2A depletion in breast cancer cells inhibited proliferation and increased paclitaxel-induced apoptosis.
|
25086622 |
2014 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The second part emphasizes the overexpression of SET and CIP2A in cancer progression, and the anticancer activity of SET antagonists as follows: (5) isolation and characterization of SET; (6) isolation and characterization of CIP2A; (7) progression of leukemia with SET; (8) progression of breast cancer with SET and CIP2A; (9) progression of lung cancer with SET; (10) anti-carcinogenic effects of SET antagonists OP449 and FTY720; and also (11) TNF-α-inducing protein of Helicobacter pylori, which is a clinical example of the okadaic acid pathway.
|
30341686 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these results implicate the E2F1-CIP2A feedback loop as a key determinant of breast cancer cell sensitivity to senescence induction.
|
23306062 |
2013 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CIP2A expression also significantly related to chemotherapeutic sensitivity of breast cancer in the neoadjuvant chemotherapy.
|
23471718 |
2013 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Loss of CIP2A also inhibited anchorage-independent growth in breast cancer cells.
|
19671842 |
2009 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently identified oncoprotein that is overexpressed in breast cancer.
|
28938602 |
2017 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The p90 ribosomal S6 kinase (RSK) is a family of MAPK-activated serine/threonine kinases (RSK1-4) whose expression and/or activity are deregulated in several cancers, including breast cancer.
|
27028868 |
2016 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The serum CIP2A levels in patients with breast cancer were (79.0 ± 74.2) ng/mL, which was significantly higher than that in those controls (25.6 ± 21.4) ng/mL for male and (24.8 ± 20.6) ng/mL for female control.
|
26813457 |
2016 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of SET or CIP2A reduces the tumorigenic potential of breast cancer cell lines both in vitro and in vivo.
|
24927563 |
2014 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CIP2A expression predicts recurrences of tamoxifen-treated breast cancer.
|
29034804 |
2017 |
Liver carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data demonstrated that miR-548b-3p was downregulated in HCC. miR-548b-3p regulates proliferation, apoptosis and mitochondrial function by targeting CIP2A in HCC.
|
30671469 |
2018 |
Liver carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Previously, we demonstrated that cancerous inhibitor of protein phosphatase 2A (CIP2A) mediates bortezomib-induced apoptosis in hepatocellular carcinoma cells.
|
22085493 |
2012 |
Liver carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
|
25077545 |
2014 |